UPDATE: Barrington Research Initiates LeMaitre Vascular at Outperform on Valuation, Stable Outlook

Barrington Research initiated coverage on LeMaitre Vascular LMAT with an Outperform rating and a $7.50 price target. Barrington Research commented, "We are initiating coverage of LMAT with an OUTPERFORM investment rating and a $7.50 price target based on our belief that LMAT has built a strong and sustainable business in the vascular surgery market and its valuation is very attractive. … With a strong surgical product portfolio, a knowledgeable and focused sales force, good relationships with a large percentage of vascular surgeons, LMAT is looking to leverage these market leadership positions by offering complementary products in larger, more competitive markets. LMAT has been an astute acquirer the past 15 years and we expect this strategy to continue." LeMaitre Vascular closed at $5.98 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationIntraday UpdateAnalyst RatingsBarrington Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!